Business Wire

Bacardi Limited Welcomes Consumer Goods Executive Dave Ingram to Lead Operations

Share

Bacardi Limited, the world’s largest privately held spirits company, today announces the appointment of Dave Ingram as Chief Supply Chain Officer. Dave brings 30 years of supply chain and strategic sourcing experience to Bacardi where he will lead the end-to-end supply chain experience -- from achieving our goal of sustainably sourcing key ingredients, to leading operations sites across the globe, to managing a robust supply chain track that brings products to shelves and consumers’ hands.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005218/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Bacardi Limited announces the appointment of Dave Ingram as Chief Supply Chain Officer (Photo: Business Wire)

Dave will report to Chief Executive Officer Mahesh Madhavan and joins the company’s Global Leadership Team effective September 1, 2022. He will be based in Geneva, Switzerland.

This appointment follows the retirement of Jean-Marc Lambert after more than 20 years with the Bacardi operations organization. Jean-Marc will remain on board through the end of the fiscal year until April 1, 2023, to support the transition.

Dave joins from Unilever where he most recently served as Chief Procurement Officer with responsibility for global spend across marketing, business services, production items and collaborative manufacturing portfolios. Prior to this role, he led regional Supply Chain teams for more than a decade as a senior executive in Europe, Asia and North Asia. His experience at Unilever began at market levels leading supply chain for Mexico and the United Kingdom.

“Dave’s passion for leading with purpose and ensuring a long-term sustainable business model makes him a great fit as we continue building on the future legacy of Bacardi. His global experience, collaborative approach, digital focus and leadership style will be an asset to our team and to our customers across the world,” says Mahesh Madhavan, Chief Executive Officer of Bacardi Limited. “We are excited to welcome him as he delivers on dynamic sourcing that will bring our iconic brands to consumers in the most efficient and responsible way possible.”

Dave brings a true global view to the role having worked in Singapore, Amsterdam, Shanghai, Mexico and the United Kingdom.

“I believe in the power of leading with a purpose and Bacardi exemplifies this through its incredible heritage, strong values, iconic brands and its commitment to quality and passion for innovation,” says Dave Ingram. “The ambitious vision for the future of Bacardi is an exciting next adventure for me and the wider team.”

Originally from Scotland, Dave holds a Bachelor of Mechanical Engineering from Heriot-Watt University in Edinburgh, serves on the Board of The Procurement Leaders, and is fluent in English and Spanish.

About Bacardi Limited

Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 160 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000, operates production facilities in 10 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on Twitter, LinkedIn or Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jessica Merz
VP Global Corporate Communications
jmerz@bacardi.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease29.11.2022 13:00:00 CET | Press release

Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD). The Phase 2 trial of INV-202, a first-in-class, peripherally-acting CB1 inverse agonist, is a multi-centered, randomized, double-blind, placebo-controlled study that will evaluate the albumin to creatinine ratio in up to 240 adult subjects with type 1 and type 2 diabetes and DKD. Participants will receive once-daily oral doses of 10 or 25mg of INV-202 or placebo during the 16-week study. Additional trial information can be found at https://clinicaltrials.gov/ via the identifier NCT05514548. This study builds on positive Phase 1b data that will be presented at a future scientific conference. It is also supported by evidence from pre-clinical data, first presented at the European Renal Association meeting in Ju

BGI Preparing to Launch Improved Non-invasive Colorectal Cancer Screening Test, COLOTECT™ 3.029.11.2022 11:54:00 CET | Press release

COLOTECT™ 3.0 is a non-invasive colorectal cancer screening test developed by BGI, and will be launched in early 2023. BGI plans to release pre-clinical case-control data for COLOTECT™ 3.0 at the 2023 ASCO Gastrointestinal Cancers Symposium. The sensitivity for detecting CRC is 96.08%. The sensitivity for detecting advanced precancerous lesions (APL) is 52.5%, which is better than FIT products. COLOTECT™ 3.0 is a non-invasive colorectal cancer (CRC) self-sampling test that can detect the methylation status of exfoliated cell genes and the Fecal Occult Blood in the stool. It can help screen for colorectal cancer and advanced precancerous lesions (APL) even in the absence of active bleeding lesions. Colorectal cancer is the third most common cancer and the second deadly cancer worldwide. There were more than 1.9 million new cases of colorectal cancer in 2020. Older age, a history of bowel disease, a family history of related diseases, having type 2 diabetes, overweight or obesity, certai

Talkdesk Chosen as Wallbox Contact Center Solution29.11.2022 11:30:00 CET | Press release

Talkdesk®, Inc., a global cloud contact center leader for customer-obsessed companies, has been selected by Wallbox as its contact center solution provider. Wallbox selected the Talkdesk solution as part of a digital transformation for their contact center, improving both agent engagement and customer experience (CX). Wallbox is an EV charging and energy management company dedicated to changing the way the world uses energy. The company, headquartered in Barcelona, develops advanced EV charging systems that allow users to better manage their energy use and storage, redefining reliance on the energy grid. With offices worldwide, customers across 113 countries, and a geographically diverse workforce of over 1,000 people, Wallbox is committed to eliminating the barriers to EV adoption and helping to accelerate a global transition to more sustainable, efficient, and smart mobility. Talkdesk CX Cloud™, an end-to-end customer experience solution, will provide Wallbox with a modernized, cloud

Kaneka to Manufacture and Supply Intermediates for Shionogi COVID-19 Drug29.11.2022 11:26:00 CET | Press release

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka) will manufacture and supply intermediates to Shionogi & Co., Ltd. (Headquarters: Chuo-ku, Osaka; Chief Executive Officer: Isao Teshirogi, Ph.D.) for use in Xocova®*1 (Ensitrelvir Fumaric Acid) Tablets 125mg, a drug for the treatment of SARS-Cov-2 infection. On November 22, Shionogi received emergency regulatory approval from the Ministry of Health, Labour and Welfare to manufacture and sell Xocova® tablets for treating SARS-Cov-2 infection. Shionogi recognized Kaneka for its long years of experience in manufacturing raw materials for medicines, and selected Kaneka as its main supplier for the drug's intermediates, which require GMP*2 management. The two companies have worked closely together for clinical development, approval application, and establishment of mass production supply chain. Kaneka will continue to improve its manufacturing systems and provide Shionogi with a stable supply of intermediates, play

Truvant Receives Procter & Gamble External Business Partner Excellence Award29.11.2022 10:00:00 CET | Press release

Packaging services provider Truvant is pleased to announce that it has received the Procter & Gamble External Business Partner Excellence Award in recognition of Truvants performance and long-standing relationship with the consumer goods giant. The External Business Partner Excellence Award was created by P&G to honor the contributions of those suppliers that have "gone above and beyond in delivering value" to the business. Truvant is the largest pure-play packaging services provider in the world, delivering manufacturing, packaging, and display solutions to the world’s leading brands. The company delivers high-quality, flexible, efficient, and sustainable packaging solutions that help brands get their products to the consumer in the most efficient way possible. Truvants solutions are designed to reduce costs, improve speed to market, create agility and manage complexity while reducing the impact on the environment. Procter & Gamble is one of the many long-standing clients that have be

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom